Get updates from ProMIS Neurosciences, Inc. (PMN) Press Releases via email, on your phone or read them on follow.it on your own custom news page.
You can filter the news from ProMIS Neurosciences, Inc. (PMN) Press Releases that get delivered to you using tags or topics or you can opt for all of them. Unsubscription is also very simple.
See the latest news from ProMIS Neurosciences, Inc. (PMN) Press Releases below.
Site title: ProMIS Neurosciences, Inc. (PMN)
Is this your feed? Claim it!
Large, well-powered Phase 1b study, designed to generate clinically and biologically meaningful insights in early Alzheimer’s disease
Clear and near-term value inflection points, with blinded 6-month interim data expected in Q2 2026 and final unblinded top-line results anticipated in Q4 2026
Cambridge, Massachusetts...
Results support the potential of PMN310 to improve outcomes by selectively targeting oligomers and avoiding binding to monomer and plaque
ProMIS on track to complete enrollment in PRECISE-AD trial in Alzheimer’s disease by end of 2025 with planned Q2 2026 interim readout
Cambridge, Massachusetts,...
Cross-trial analysis supports plasma pTau as a potential early predictor of clinical benefit, reinforcing the biomarker-driven design of ProMIS’ PRECISE-AD trial
ProMIS on track to leverage new plasma pTau insights with planned Q2 2026 interim readout
Cambridge, Massachusetts, Dec. 01, 2025 (GLOBE NEWS...
Cambridge, Massachusetts, Dec. 01, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, will be participating in a fireside c...
Cambridge, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced that its board of directors has determined to effect a one-for-twenty-five reverse stock split of the Compa...
